Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 3/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5204377 | 0.94 | POLB (0.49) | MAPTALDH1A1MAPK1SYKMCHR1 | |
| SCHEMBL9660476 | 0.83 | MAPT (0.56) | MAPTALDH1A1MAPK1MCHR1NPBWR1 | |
| SCHEMBL3552397 | 0.83 | MAPT (0.56) | MAPTALDH1A1MAPK1MCHR1NPBWR1 | |
| SCHEMBL3552399 | 0.83 | MAPT (0.56) | MAPTALDH1A1MAPK1MCHR1NPBWR1 | |
| SCHEMBL3554528 | 0.82 | MAPT (0.48) | MAPTALDH1A1MAPK1SYKMCHR1 | |
| SCHEMBL3885054 | 0.82 | MAPT (0.61) | MAPTALDH1A1MAPK1MCHR1NPBWR1 | |
| SCHEMBL13724767 | 0.81 | SYK (0.49) | MAPTALDH1A1SYK | |
| SCHEMBL3550347 | 0.81 | SYK (0.49) | MAPTALDH1A1SYK | |
| SCHEMBL28149835 | 0.80 | MAPT (0.44) | MAPTALDH1A1MAPK1MCHR1NPBWR1 | |
| SCHEMBL4714684 | 0.79 | MAPT (0.53) | MAPTALDH1A1MAPK1MCHR1NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655652-B2 | 2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine hydrochloride; cell cycle inhibitory; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | disclosed |
| US-20070161615-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| EP-1748999-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005075461-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161615-A1 | Chemical compounds | MKI67, PCNA, CCNI | MAPT 3632/4885ALDH1A1 320/4885MAPK1 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.